Instituto Nacional de Cancerología - Ciudad de México
Instituto Nacional de Cancerología - Ciudad de México
Avenida San Fernando 22, México DF
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Rodrigo Espinosa
Oscar G Arrieta
Open studies
Lung cancer
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations - METLUNG - Instituto Nacional de Cancerologia de MexicoSee more
Alectinib Pharmacokinetic in Patients With NSCLC - Instituto Nacional de Cancerologia de MexicoSee more
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC - Instituto Nacional de Cancerologia de MexicoSee more
Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients - Instituto Nacional de Cancerologia de MexicoSee more
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. - Instituto Nacional de Cancerologia de MexicoSee more
Advanced tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy - INAVO121 - Hoffmann-La RocheSee more
Cervical cancer
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer - MICHELE - National Institute of CancerologíaSee more
Esophageal cancer
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin - CheckMate 648 - Ono Pharmaceutical Co. LtdSee more
Lymphoma
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma - GO44145 - Hoffmann-La RocheSee more
Non-Hodgkin Lymphoma
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma - GO44145 - Hoffmann-La RocheSee more
Ovarian cancer
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention - TUBA-WISP-II - University Medical Center NijmegenSee more
Prostate cancer
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer - Southwest Oncology GroupSee more
Solid tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) - MK-3475-587 - Merck Sharp & Dohme Corp.See more
